MNPR (Monopar Therapeutics) Net Margin %: 0.00% (As of Mar. 2026)

What is Monopar Therapeutics Net Margin %?

Monopar Therapeutics MNPR +9.14% 35 Net Margin % is 0.00% as of Mar. 2026. GuruFocus rates MNPR with a GF Score™ of 35/100. The stock has 2 warning signs investors should review. Among 947 Biotechnology companies, Monopar Therapeutics ranks worse than 105596.52% on this metric.

Net margin is calculated as Net Income divided by its Revenue. Monopar Therapeutics's Net Income for the three months ended in Mar. 2026 was $-3.89 Mil. Monopar Therapeutics's Revenue for the three months ended in Mar. 2026 was $0.00 Mil. Therefore, Monopar Therapeutics's net margin for the quarter that ended in Mar. 2026 was 0.00%.

The historical rank and industry rank for Monopar Therapeutics's Net Margin % or its related term are showing as below:

MNPR's Net Margin % is not ranked ^*
in the Biotechnology industry.
Industry Median: -89.33
* Ranked among companies with meaningful Net Margin % only.

Monopar Therapeutics (NAS:MNPR) Net Margin % Explanation

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.

Monopar Therapeutics Net Margin % Related Terms

Monopar Therapeutics Net Margin % Historical Data

* Premium members only.

The historical data trend for Monopar Therapeutics's Net Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Monopar Therapeutics Net Margin % Chart

Monopar Therapeutics Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

Net Margin %

Get a 7-Day Free Trial

0.00

Monopar Therapeutics Quarterly Data
	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26
Net Margin %	Get a 7-Day Free Trial															0.00	0.00	0.00	0.00	0.00

MNPR vs IPSC, ADCT, CMPX: Net Margin % Comparison

For the Biotechnology subindustry, Monopar Therapeutics's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Monopar Therapeutics Net Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Monopar Therapeutics's Net Margin % distribution charts can be found below:

* The bar in red indicates where Monopar Therapeutics's Net Margin % falls into.

Save Embed

35GF Score

Monopar Therapeutics Inc MNPR

Net Margin % is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Monopar Therapeutics Net Margin % Calculation

Net margin - also known as net profit margin is the ratio of Net Income divided by net sales or Revenue, usually presented in percent.

Monopar Therapeutics's Net Margin for the fiscal year that ended in Dec. 2025 is calculated as

Net Margin	=	Net Income (A: Dec. 2025 )	/	Revenue (A: Dec. 2025 )
	=	-13.717	/	0
	=	%

Monopar Therapeutics's Net Margin for the quarter that ended in Mar. 2026 is calculated as

Net Margin	=	Net Income (Q: Mar. 2026 )	/	Revenue (Q: Mar. 2026 )
	=	-3.893	/	0
	=	%

Frequently Asked Questions Learn more about Net Margin % →

What does a Net Margin % of 0.00% mean?

Monopar Therapeutics (MNPR) has a Net Margin % of 0.00% as of Mar. 2026. Net margin is the ratio of total net income to net sales. View historical data on Monopar Therapeutics and its competitors. According to the industry distribution chart, Monopar Therapeutics ranks #999999 out of 947 companies in the Biotechnology industry.

Is Monopar Therapeutics' Net Margin % too high?

Monopar Therapeutics' current Net Margin % is 0.00%. Based on the distribution chart, Monopar Therapeutics ranks #999999 out of 947 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Monopar Therapeutics has a GF Score™ of 35/100, reflecting its overall financial health beyond just this single metric.

How does Monopar Therapeutics' Net Margin % compare to IPSC and ADCT?

According to the Biotechnology industry distribution chart, Monopar Therapeutics ranks #999999 out of 947 companies for Net Margin %. This places Monopar Therapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good Net Margin % for a Biotechnology company?

A good Net Margin % depends on the Biotechnology industry context. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high Net Margin % mean?

A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Monopar Therapeutics and its competitors. Monopar Therapeutics's current Net Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Monopar Therapeutics stock overvalued right now?

Monopar Therapeutics (MNPR) has a current Net Margin % of 0.00%. The current Net Margin % is 0.00%. Monopar Therapeutics' overall GF Score™ is 35/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is Net Margin % calculated?

Net Margin % is calculated from a company's financial statements. For Monopar Therapeutics (MNPR), the current Net Margin % is 0.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Monopar Therapeutics Business Description

Industry Healthcare Biotechnology

Comparable Companies IPSC ADCT CMPX NGNE SGMT UPB STTK CYDY FULC OCGN VRTX REGN XBRU:UCB XBRU:ARGX XKRX:207940 ALNY RVMD ASX:CSL ONC XKRX:068270

Address 1000 Skokie Boulevard, Suite 350, Wilmette, IL, USA, 60091

Website https://www.monopartx.com

Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company developing a treatment for Wilson disease and novel radiopharmaceuticals for oncology. Its Wilson disease product candidate is ALXN1840, a late-stage, investigational once-daily, oral medicine. The group radiopharmaceutical programs consist of Phase 1-stage MNPR-101-Zr for imaging cancers, and Phase 1a-stage MNPR-101-Lu and late preclinical-stage MNPR-101-Ac for the treatment of cancers that express urokinase plasminogen activator receptor (uPAR). It build drug development pipeline through both in-house efforts and licensing of late preclinical- and clinical-stage therapeutics. The Company operates as a single reportable segment, focusing on the development of clinical and preclinical product candidates.

35GF Score

Get the complete analysis for MNPR

Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$89.10

Price

View MNPR Analysis

See Net Margin % data for all stocks →